Bipartisan Health Care Act

Bill Number: S. 891
Origin Chamber: Senate
Congress: 119th Congress, Session 1
Policy Area: Health
Status: Introduced
Latest Action: 2025-03-06: Read twice and referred to the Committee on Finance.
Last Updated: 2026-06-11T18:45:20Z

AI-Generated Summary

Summary of S. 891: Bipartisan Health Care Act

Purpose

The legislation aims to extend expiring federal health programs, enhance access to and delivery of health care services, improve program integrity, and address public health challenges. It focuses on extending funding for Medicaid and Medicare provisions, reauthorizing substance use disorder initiatives, bolstering pandemic preparedness, supporting specific public health efforts (e.g., maternal and child health), advancing FDA pediatric drug research, and increasing transparency in prescription drug pricing to lower costs.

Key Provisions

The bill is organized into 10 titles, addressing various aspects of health policy:

Title I: Medicaid
Streamlines enrollment for out-of-state providers serving children under Medicaid/CHIP.
Adjusts home- and community-based services (HCBS) coverage, including transparency requirements for waitlists and service delivery times.
Removes age limits (under 65) for working adults with disabilities to access Medicaid buy-in programs.
Ensures residency rules for military families and reliable address verification to prevent improper enrollments.
Codifies screening for deceased providers/enrollees using the Death Master File.
Delays certain juvenile justice health screening requirements by one year and mandates state work plans.
Requires studies on maternity service costs and adjusts disproportionate share hospital (DSH) payments.
Prohibits abusive spread pricing by pharmacy benefit managers (PBMs) and ensures accurate pharmacy reimbursements.

Title II: Medicare
Extends payment adjustments for low-volume hospitals, Medicare-dependent hospitals, and ambulance services.
Prolongs incentives for alternative payment models and telehealth flexibilities (e.g., no geographic limits until 2026).
Adds coverage for multi-cancer early detection tests (starting 2029), external infusion pumps, and virtual diabetes prevention.
Enhances program integrity for durable medical equipment (DME) and requires PBM accountability.
Adjusts Part D cost-sharing for low-income individuals and extends sequestration limits.

Title III: Human Services
Extends funding for sexual risk avoidance and personal responsibility education programs.
Continues support for family-to-family health information centers.

Title IV: Public Health Extenders
Extends funding for community health centers, National Health Service Corps, teaching health centers, and special diabetes programs.
Corrects funding for the World Trade Center Health Program for 9/11 responders/survivors.

Title V: SUPPORT Act Reauthorization
Reauthorizes opioid/substance use disorder programs through 2029, covering prevention (e.g., prenatal health, overdose monitoring), treatment (e.g., residential programs for pregnant women, loan repayment for workforce), recovery (e.g., peer support, youth programs), and miscellaneous (e.g., fentanyl scheduling extension).

Title VI: Pandemic and All-Hazards Preparedness and Response
Enhances state/local readiness (e.g., personnel reassignment, stockpiles, wastewater surveillance).
Improves federal coordination (e.g., national strategy, diagnostic tests, antimicrobial resistance).
Addresses needs of at-risk individuals and reauthorizes programs like medical countermeasures and volunteer systems.

Title VII: Public Health Programs
Funds dental health, preterm birth research (PREEMIE), maternal mortality prevention, sickle cell disease, traumatic brain injuries, respite care, provider protection, cancer screenings, Down syndrome research (INCLUDE Project), maternal health (IMPROVE Initiative), and organ donation.

Title VIII: Food and Drug Administration
Advances pediatric drug research (Give Kids a Chance) and establishes an Abraham Accords Office for international regulatory cooperation.

Title IX: Lowering Prescription Drug Costs
Mandates PBM oversight, full rebate pass-through to plans, and transparency in generic applications.

Title X: Miscellaneous
Extends safe harbor for telehealth without deductibles under HSAs.

Significant Changes to Existing Law

Medicaid/Medicare Extensions: Prolongs numerous temporary provisions (e.g., telehealth flexibilities to 2026, low-volume hospital payments to 2027) and introduces new ones (e.g., multi-cancer screening coverage, PBM spread pricing ban).
PBM Reforms: Requires full rebate pass-through, prohibits spread pricing, and mandates detailed reporting on drug costs, formularies, and affiliations (effective 30 months post-enactment).
Pediatric Drugs: Expands FDA authority for molecularly targeted cancer drugs in pediatrics, including combinations with standard-of-care treatments; limits orphan drug exclusivity for same indications.
Substance Use/Opioids: Reauthorizes SUPPORT Act with expansions (e.g., fentanyl education, wastewater surveillance for overdoses).
Pandemic Prep: Adds wastewater surveillance for pathogens; limits funding for high-risk research in "countries of concern" (e.g., China, Russia).
Organ Donation: Enhances OPTN duties (e.g., electronic records integration) and allows registration fees (sunsets in 3 years).

Potential Impacts

Government Agencies: Increases workload for HHS/CMS (e.g., new reporting, audits, guidance issuance) but provides funding (e.g., $71M for HCBS demos, $188M for pharmacy access). Enhances FDA's international role via Abraham Accords Office, potentially straining resources.
Citizens: Improves access to care (e.g., telehealth, HCBS for military families/disabled adults, cancer screenings) and reduces costs (e.g., PBM transparency, lower Part D sharing). Benefits vulnerable groups (e.g., pregnant women, sickle cell patients, 9/11 survivors) but may delay some services (e.g., juvenile screenings).
International Relations: Strengthens U.S.-Abraham Accords ties through FDA office; restricts research funding in adversarial nations, potentially affecting global collaborations.

Main Stakeholders Affected

Health Care Providers/Plans: Hospitals, pharmacies, PBMs face new compliance/reporting burdens but gain streamlined enrollments and payment extensions.
Patients/Beneficiaries: Low-income, disabled, military families, substance use disorder patients, and pediatric/rare disease groups benefit from expanded access and lower costs.
Pharmaceutical Industry: Drug makers face pediatric study mandates and orphan exclusivity limits; generics gain transparency in applications.
States/Tribes: Receive extended funding and tools (e.g., maternity cost studies, opioid grants) but must implement new requirements (e.g., address verification).
Government: HHS/FDA/CMS handle oversight/enforcement; taxpayers fund extensions (e.g., $4.6B for health centers in FY2026).

Notable Legal, Constitutional, or Political Implications

Legal: Enhances antitrust scrutiny on PBMs/pharma via transparency/rebate rules; aligns with HIPAA/privacy laws but adds enforcement (e.g., civil penalties up to $100K). Pediatric provisions balance innovation incentives with child safety under FDA authority.
Constitutional: Supports equal protection by addressing disparities (e.g., rural/military access, maternal health in underserved areas); no direct challenges noted.
Political: Bipartisan focus on opioids, maternal health, and drug costs appeals across aisles; extends Trump/Biden-era programs (e.g., SUPPORT Act, pandemic prep) amid fiscal debates over funding ($ billions in appropriations). Potential for litigation on PBM rebates if seen as overreach on contracts.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Wyden, Ron [D-OR]

Cosponsors (1)

Sen. Sanders, Bernard [I-VT]

Recent Actions

2025-03-06: Read twice and referred to the Committee on Finance.
2025-03-06: Introduced in Senate

Bill Versions

Bipartisan Health Care Act — issued 2025-03-06 — PDF (482 pages)